Phase 3 Study of Loncastuximab Tesirine, an Anti-CD-19 Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
For more information about the trial above please contact the study team:
Principal Investigator, Brian Hess, at email@example.com.
Study Coordinator, Sarah Britton, at firstname.lastname@example.org, or please call +1 843-792-8856.
Trial opened at the following institutions: Medical University of South Carolina